Ubiquigent extends collaboration with Bristol Myers Squibb 

Ubiquigent will provide Bristol Myers Squibb with increased access to its deubiquitylase (DUB) enzyme inhibitor drug discovery platform to provide support to therapeutic areas, in an extension of the companies’ long-term collaboration. 

Ubiquitylation in diverse cellular processes, including but not limited to protein degradation, makes the enzymes responsible for ubiquitylation and de-ubiquitylation highly attractive drug targets with the potential to address a wide range of human pathologies.  

Recently, there has been further growing interest in the development of modulators of various components of the ubiquitin-proteasome system (UPS) for therapeutic benefit. Strategies that are being actively pursued include the exploitation of the UPS via PROTACs and molecular glues to target the undruggable proteome and the development of DUB inhibitors. 

Ubiquigent CEO Jason Mundin, said: “We are delighted to have the opportunity to build on our existing relationship with Bristol Myers Squibb in this rapidly evolving field to provide additional support to the development of novel DUB inhibitors for patients with unmet medical needs.” 

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free